interdigitating dendritic cell sarcoma
interdigitating dendritic cell sarcoma
Explore linked clinical trials. Standard reference: MONDO:000581360 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm | Recruiting | Not stated | 2026-10-09 | NCT05377307 | |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, high grade B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, indolent B-cell non-Hodgkin lymphoma, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, primary mediastinal large B-cell lymphoma | Active, not recruiting | Phase 1 | 2026-10-08 | NCT05621096 | |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-10-05 | NCT05641428 | |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | B-cell neoplasm, Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, diffuse large B-cell lymphoma, heart disorder, heart failure, histiocytosis, immune system disorder, immunoproliferative disorder, injury, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, radiation injury | Recruiting | Phase 3 | 2026-09-23 | NCT06220032 | |
| CAR-T Followed by Bispecific Antibodies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, large B-cell lymphoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04889716 | |
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 2 | 2026-09-11 | NCT07812493 | |
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma | B-cell neoplasm, Digestive System Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, digestive system disorder, histiocytosis, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, primary mediastinal large B-cell lymphoma, pyloric stenosis, stomach disorder | Recruiting | Phase 1 | 2026-09-11 | NCT06830031 | |
| CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 1 | 2026-08-27 | NCT07443137 | |
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, bone marrow disorder, childhood ependymoma, hematologic disorder, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT05857969 | |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Not applicable | 2026-08-21 | NCT07778212 | |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Phase 3 | 2026-08-13 | NCT07570823 | |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Waldenstrom macroglobulinemia, cardiovascular disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-08-13 | NCT06980116 | |
| Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm | Recruiting | Phase 3 | 2026-08-10 | NCT07739654 | |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Phase 2 | 2026-08-06 | NCT07749365 | |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Richter transformation, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, marginal zone lymphoma, neoplasm | Not yet recruiting | Phase 2 | 2026-08-06 | NCT07744750 | |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 2 | 2026-08-06 | NCT07744737 | |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 2 | 2026-08-06 | NCT07744724 | |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, neoplasm, relapsed/refractory diffuse large B-cell lymphoma | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07748364 | |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, neoplasm | Recruiting | Phase 1 | 2026-07-24 | NCT07121946 | |
| Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Phase 2 | 2026-07-02 | NCT07680933 | |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Not yet recruiting | Phase 2 | 2026-07-01 | NCT07677813 | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Richter transformation, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-12 | NCT03162536 | |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, primary mediastinal large B-cell lymphoma | Enrolling by invitation | Not stated | 2026-06-11 | NCT06985576 | |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Bone Marrow Failure Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, Herpesviridae infectious disease, Hodgkins lymphoma, Infections, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute myeloid leukemia, anaplastic large cell lymphoma, anemia, angioimmunoblastic T-cell lymphoma, aplastic anemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, graft versus host disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemolytic anemia, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, juvenile myelomonocytic leukemia, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, plasma cell neoplasm, precancerous condition, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Phase 2 | 2026-06-02 | NCT00544115 | |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm | Active, not recruiting | Phase 1 | 2026-05-07 | NCT06014762 |